Literature DB >> 7142810

A re-examination of the fate of glyceride-glycerol in neutral lipid absorption and transport.

C M Mansbach, S Parthasarathy.   

Abstract

Conventional ideas concerning the unidirectional movement of triacylglycerol from intestinal lumen to lymph with sn-2-monoacylglycerol being the major glyceride-glycerol precursor were challenged by our finding that steady state specific activities of radiolabeled triacylglycerol (glyceryl moiety) in the intestinal mucosa and lumen were greatly reduced as compared to the specific activity of intraduodenally infused triacylglycerol. Investigation of the point at which the radiolabel was diluted was performed in mesenteric lymph duct-cannulated rats with a duodenal cannula through which trioleoyl[3H]glycerol was constantly infused. Both within the bowel lumen and in the intestinal mucosa, monoacylglycerol, diacylglycerol, and triacylglycerol specific activities were 31% or less of the specific activity of the infusate; chylomicron triacylglycerol specific activity was 75%. Efflux of neutral lipid from the mucosa into the bowel lumen was directly demonstrated by finding that when 3H glucose was injected intraperitoneally during triolein infusion, luminal triacylglycerol had a higher specific activity than was present in the mucosa. We conclude that there are two pools of mucosal triacylglycerol. One is rapidly transported and derives most of its glyceride-glycerol from luminal monoacylglycerol. The second is slowly transported; it derives its glyceride-glycerol mainly from endogenous sources and may efflux back into the bowel lumen.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7142810

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  15 in total

1.  Relationship of phosphatidylcholine to hydrophobic surfactant on rat intestinal chylomicron secretion.

Authors:  J B Rodgers; D A Beeler; P Tso
Journal:  Experientia       Date:  1996-07-15

2.  Phosphorylation of Sar1b protein releases liver fatty acid-binding protein from multiprotein complex in intestinal cytosol enabling it to bind to endoplasmic reticulum (ER) and bud the pre-chylomicron transport vesicle.

Authors:  Shahzad Siddiqi; Charles M Mansbach
Journal:  J Biol Chem       Date:  2012-02-01       Impact factor: 5.157

3.  Gut triglyceride production.

Authors:  Xiaoyue Pan; M Mahmood Hussain
Journal:  Biochim Biophys Acta       Date:  2011-10-02

4.  Dynamics of blood chylomicron fatty acids in a marine carnivore: implications for lipid metabolism and quantitative estimation of predator diets.

Authors:  Margaret H Cooper; Sara J Iverson; Horacio Heras
Journal:  J Comp Physiol B       Date:  2005-01-19       Impact factor: 2.200

5.  Bile increases intestinal lymphatic drug transport in the fasted rat.

Authors:  Natalie L Trevaskis; Christopher J H Porter; William N Charman
Journal:  Pharm Res       Date:  2005-08-16       Impact factor: 4.200

Review 6.  Intestinal triacylglycerol synthesis in fat absorption and systemic energy metabolism.

Authors:  Chi-Liang Eric Yen; David W Nelson; Mei-I Yen
Journal:  J Lipid Res       Date:  2014-09-17       Impact factor: 5.922

Review 7.  Overview on Microbial Enzymatic Production of Algal Oligosaccharides for Nutraceutical Applications.

Authors:  Ashok S Jagtap; Cathrine S Manohar
Journal:  Mar Biotechnol (NY)       Date:  2021-03-24       Impact factor: 3.619

8.  Milk Fat Globule structure & function; nanosciece comes to milk production.

Authors:  Nurit Argov; Danielle G Lemay; J Bruce German
Journal:  Trends Food Sci Technol       Date:  2008-12       Impact factor: 12.563

9.  Metabolism of apical versus basolateral sn-2-monoacylglycerol and fatty acids in rodent small intestine.

Authors:  Judith Storch; Yin Xiu Zhou; William S Lagakos
Journal:  J Lipid Res       Date:  2008-04-17       Impact factor: 5.922

10.  A possible role for rat intestinal surfactant-like particles in transepithelial triacylglycerol transport.

Authors:  A Mahmood; F Yamagishi; R Eliakim; K DeSchryver-Kecskemeti; T L Gramlich; D H Alpers
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.